ReviewCancer journal (Sudbury, Mass.)
Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Primary Tumor Resection in Patients With Unresectable Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.Annals of gastroenterological surgery · 2026Review
- Chondroitin polymerizing factor promotes development and progression of colorectal cancer via facilitating transcription of VEGFB.Journal of cellular and molecular medicine · 2024Article
- The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.Cancer reports (Hoboken, N.J.) · 2022Article
- Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.The Journal of surgical research · 2021Article
- CDC42EP3 promotes colorectal cancer through regulating cell proliferation, cell apoptosis and cell migration.Cancer cell international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Treatment options have improved for patients with colorectal cancer, but these improvements have invariably been more modest than had been anticipated or hoped for. Yet while outcomes have improved modestly, costs have risen substantially, as prices of the newer anticancer agents in colorectal cancer have led the way in the stratospheric rise in cancer drug prices in general. Development of future strategies that will be both sustainable and attainable by all who need them will require both an understanding of past events that have brought us to the present and a willingness to confront the limitations of our present options and to assess them for the true value that they do or do not offer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.